FindTrial
Sign In

Impact of Co-morbidity on outcomes in Head and Neck cancer patients

Impact of co-morbidity on Outcome in Head and Neck cancer Patients- A prospective longitudinal study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2013/11/004154
Enrollment
600
Registered
2013-11-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patient Having Biopsy Proven Squamous cell carcinoma of Head and Neck Cancer.

Interventions

None listed

Sponsors

Tata Memorial Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient Having Biopsy Proven Squamous cell carcinoma of Head and Neck Cancer No history of any prior anti-neoplastic treatment received in last 5 years. Patients willing for follow-up after treatment

Exclusion criteria

Exclusion criteria: Patients unreliable for follow up. Patients not willing to sign informed consent

Design outcomes

Primary

MeasureTime frame
To find out prevalence of co-morbidity in patients and to document the change in treatment, based on the severity of co-morbidity in this cohort of patients.Timepoint: To find out prevalence of co-morbidity in patients and to document the change in treatment, based on the severity of co-morbidity in this cohort of patients.—

Secondary

MeasureTime frame
To assess the impact of co-morbidity on survival (cancer and non cancer related) and the incidence of toxicities and compliance to the planned treatment.Timepoint: Baseline, Follow up- 2 years from end of accrual—

Countries

India

Contacts

Public ContactDR J P AGARWAL

TATA MEMORIAL HOSPITAL

agarwaljp@tmc.gov.in24177000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026